suPAR Biomarker Stratification for Personalized Statin Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cardiovascular disease treatments lack personalized and cost-effective approaches due to patient heterogeneity, necessitating the need for biomarkers that predict outcomes and guide therapy decisions.
Innovation Solution
Measuring soluble urokinase plasminogen activator receptor (suPAR) protein levels in patients to determine tailored treatments such as bypass surgery, stenting, statin therapy, immunomodulatory therapy, anti-suPAR therapy, chelation therapy, or organ transplantation based on suPAR thresholds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cardiovascular disease treatments are applied to all patients, then treatment coverage is comprehensive, but treatment effectiveness is reduced due to patient heterogeneity
Solution Approach 1:
The patent applies local quality by using suPAR biomarker levels to differentiate patient subgroups and assign specific treatments to each subgroup. Patients with high suPAR levels receive immunomodulatory therapy, while those with low suPAR levels receive conventional therapy, thereby optimizing treatment effectiveness for each local patient population rather than applying a uniform approach to all patients
Solution Approach 2:
The patent utilizes parameter changes by measuring suPAR protein levels as a quantitative biomarker to stratify patients into different risk categories. This parameter-based classification enables the selection of appropriate treatments (bypass surgery, stenting, statin therapy, immunomodulatory therapy, or chelation therapy) based on specific suPAR threshold values, transforming a one-size-fits-all approach into a parameter-driven personalized treatment strategy
2Reliability
If personalized treatment plans are implemented, then treatment efficacy is improved, but diagnostic complexity increases
Solution Approach 1:
The patent replaces complex clinical assessment and multiple diagnostic tests with a single biomarker measurement (suPAR level). This substitution simplifies the diagnostic process while maintaining high treatment efficacy, as the suPAR level serves as a straightforward quantitative measure that guides treatment selection without requiring complex diagnostic algorithms or multiple testing procedures
Solution Approach 2:
The patent simplifies diagnostic complexity by reducing the diagnostic workflow to a single key parameter measurement (suPAR level) with clear threshold-based interpretation. Instead of requiring complex multi-parameter assessments, the patent uses one critical biomarker parameter to stratify patients and guide treatment decisions, thereby improving treatment efficacy while minimizing diagnostic complexity
3Measurement precision
If comprehensive patient evaluation is performed, then treatment accuracy is improved, but treatment cost increases
Solution Approach 1:
The patent extracts the essential predictive information from complex patient evaluation by focusing on a single key biomarker (suPAR level). This extraction approach achieves high treatment accuracy by identifying the most critical predictive parameter, while avoiding the need for comprehensive and costly evaluations of all potential risk factors, thereby reducing treatment costs without sacrificing accuracy
Solution Approach 2:
The patent improves the ratio of treatment accuracy to cost by utilizing a single, measurable parameter (suPAR level) that provides high predictive value. This parameter-based approach achieves treatment accuracy comparable to comprehensive evaluations but at a fraction of the cost, as it eliminates the need for multiple expensive tests and complex assessments while maintaining precise treatment stratification
Data Source
AI summary
The disclosure is directed to methods for preventing or treating cardiovascular disease and kidney dysfunction in certain patient populations which involve determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject, and performing various therapeutic interventions based on the suPAR level in the sample.